# TriApex Laboratories

TriApex Laboratories is a Nonclinical and clinical drug development CRO based in Beijing, China.

## Overview

- **Organization type:** Nonclinical and clinical drug development CRO
- **Headquarters:** Beijing, China
- **Region:** Asia
- **Address:** Beijing, China
- **Founded:** 2008
- **Assets under management:** Undisclosed
- **Website:** https://www.tri-apex.com
- **LinkedIn:** https://www.linkedin.com/company/tri-apex

## Regulatory record

- **Reports private funds:** No

## About

TriApex Laboratories is a China-based contract research organization (CRO) with facilities in Beijing, Nanjing, and Shenzhen. The firm focuses on non-clinical safety assessment and drug metabolism and pharmacokinetics (DMPK) studies, serving pharmaceutical and biotechnology developers that require mandatory regulatory data packages before first-in-human dosing. The firm's core offerings center on Good Laboratory Practice (GLP)-compliant toxicology, safety pharmacology, and bioanalytical services. Its operational footprint spans multiple major biotech hubs in China, specifically Beijing, Nanjing's Jiangbei New Area biomedical cluster, and Shenzhen's Nanshan district life science corridor. The multiple-site structure is typical of Chinese CROs that locate facilities near both academic talent pools and industrial sponsor concentrations. TriApex's service lines address the outsourced safety-testing requirements that Western and Chinese biotech firms must satisfy under CFDA and OECD guidelines, positioning it as a vendor for preclinical development programs rather than a direct investment firm. The firm's scale, leadership, and ownership structure are not publicly disclosed. TriApex Laboratories does not appear to market itself to institutional allocators or maintain a public-facing investment profile, which is consistent with an operating company in the CRO sector rather than a family office or asset manager. In May 2024, no specific operational event was publicly reported, and the entity's transaction history, if any, remains unverifiable through open sources. TriApex is structurally a service provider, not a capital allocator. Its differentiation lies in its multi-site licensure for GLP toxicology, which is a capacity-constrained and regulatorily gated function — each facility must secure and maintain certifications separately, creating operational moats rather than investment moats.

## Offices

- Nanjing, China
- Shenzhen, China

## Questions

### What services does TriApex Laboratories provide?

TriApex focuses on non-clinical safety assessment, including GLP-compliant toxicology, safety pharmacology, and DMPK (drug metabolism and pharmacokinetics) studies. These services generate the regulatory data packages required by agencies like the CFDA and OECD before a new drug candidate can proceed to human clinical trials.

### Where are TriApex Laboratories' facilities located?

The firm maintains operations in three major Chinese life science hubs: Beijing, Nanjing, and Shenzhen. The Nanjing site is positioned within the Jiangbei New Area biomedical cluster, while the Shenzhen presence aligns with the Nanshan district's concentration of life science companies.

### Who owns or runs TriApex Laboratories?

TriApex's ownership structure, founding principals, and current leadership team are not disclosed in public records. The firm operates as a private entity in the CRO sector and does not publish organizational details, executive biographies, or equity structure information.

## Related profiles

- [Innovation Fund](https://altss.com/profile/innovation-fund)
- [Jollibee Foods Corporation](https://altss.com/profile/jollibee-foods-corporation)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/triapex-laboratories-co

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology